Colorectal cancer could see Array stand alone at last
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
Biomarin hopes long-term valrox data can stem the bleeding
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Abbott shifts to tricuspid repair
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Company Events
Biomarin hopes long-term valrox data can stem the bleeding
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Reata’s big test approaches
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
Interviews
Who will capitalise on CAR-T at last? Not big pharma, says Tmunity
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Mustang Bio sets its sights on 2021 approval
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
Astra makes machine learning bet with Benevolent AI deal
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…